Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but real-world patient-reported experiences are under-described. We evaluated real-world self-efficacy and experiences with tirzepatide in community settings. Methods: Explanatory sequential mixed-methods study of adults aged 18–59 years using tirzepatide for weight management. We collected a quantitative survey (demographics; medication use; 20-item Weight Efficacy Lifestyle Questionnaire [WEL]) followed by purposive semi-structured interviews. Associations between WEL and participant characteristics were tested a priori (two-tailed α = 0.05). Results: Among 120 participants (50.8% male; mean age 42 ± 13 years), 91.7% reported weight loss and 85.8% had <6 months’ exposure. WEL total was 91 ± 34. Higher WEL was observed in females, employed participants, those with insurance coverage versus self-pay, during early months of therapy, and among those with prior weight-loss attempts (all p < 0.05). Interviews (n = 15) indicated high satisfaction, improved sleep/energy, mood, and confidence; gastrointestinal effects were usually mild/transient. Interpretation: In routine care, tirzepatide use was associated with high eating self-efficacy and positive patient-reported outcomes. Variation by coverage and duration suggests value in pairing pharmacotherapy with behavioral support and addressing affordability to sustain benefits.

Background: Improper disposal of unused and expired medications poses environmental and public health risks. Non‑medical service providers may be insufficiently informed about safe disposal practices. Purpose: To evaluate whether a structured teaching program improves knowledge, attitudes, and practices related to the safe disposal of unused medicines among non‑medical staff at a UAE university. Methods: A pre‑experimental one‑group pre‑test/post‑test design was employed with 37 participants. A validated questionnaire assessed knowledge, practices, and attitudes. Data were analyzed in SPSS v27 using paired t‑tests and chi‑square tests (p < .05). Results: Knowledge increased from a pre‑test mean of 5.32 (SD = 2.62) to 8.94 (SD = 3.05), t(36) = –7.597, p < .001. Attitude totals improved from 38.51 (SD = 8.16) to 41.54 (SD = 4.58), t(36) = –2.23, p = .032. Despite higher awareness, some participants continued to dispose medicines in household garbage, although returns to pharmacies increased. A significant association between knowledge and attitude categories was observed (χ² = 38.91, df = 2, p < .001); exploratory post‑test correlation was weak and non‑significant. Conclusion: The structured teaching program improved knowledge and overall attitudes. Sustainable behavior change will likely require convenient disposal options and periodic refreshers.

Background: Continuous glucose monitoring (CGM) has been increasingly adopted for the management of type 2 diabetes mellitus (T2DM); however, real‑world comparative evidence from the United Arab Emirates comparing CGM with self‑monitoring of blood glucose (SMBG) remains limited and inconclusive, making definitive conclusions difficult. Aim: To compare glycaemic control and quality-of-life outcomes between adults with T2DM using CGM and those using SMBG in Dibba Fujairah, UAE. Methods: A quantitative, comparative observational study was conducted using clinical records from 416 adults with T2DM (204 CGM users and 212 SMBG users). Glycaemic control was assessed using baseline and follow-up glycated hemoglobin (HbA1c) values, and quality of life was assessed using a single‑item, self‑reported scale ranging from 1 to 10, as recorded in patient medical records. Results: CGM users were significantly younger than SMBG users (M = 48.63 vs. 54.73 years; p < .001) and had a shorter duration of diabetes (M = 9.09 vs. 14.65 years; p <.001). Baseline HbA1c was significantly higher in the CGM group (M = 9.61% vs. 8.01%; t (334.9) = 5.21, p < .001, d = 0.52). No statistically significant between-group differences were observed in single-item quality-of-life scores at baseline (p = .142) or follow-up (p = .605). Multiple linear regression predicting baseline HbA1c was statistically significant (R² = .622), with CGM use, gender, and baseline quality of life emerging as significant predictors. Conclusion: CGM was associated with differential glycaemic profiles and superior statistical performance in glycaemic outcomes; however, quality-of-life advantages were not observed on the single-item measure. Evidence of Channeling bias, which is when patients are preferentially assigned to a regimen based on their characteristics rather than at random, which can skew real‑world comparisons between treatments. Underscores the importance of cautious interpretation when evaluating real-world CGM effectiveness.